Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

TScan Therapeutics, Inc. Common Stock

TCRX

TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

Last trade $0.1438
Day change -$0.0013 (-0.90%)
Day range $0.14 – $0.166
Volume 181,162
Market cap $10M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$10.17M
Price / earnings
—
Price / book
0.27×
Price / sales
1.96×
EV / sales
-5.77×
EV / EBITDA
0.26×

Profitability

Earnings per share
-$1.70
Return on assets
-81.39%
Return on equity
-302.77%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.87×
Current ratio
2.03×
Quick ratio
2.03×
Cash ratio
1.93×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$111.27M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for TCRX, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$586K$1.05M$982K$2.57M$2.51M$3.08M$2.17M$665K
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$586K$1.05M$982K$2.57M$2.51M$3.08M$2.17M$665K
Selling, general and administrative$8.33M$8.14M$8.22M$6.39M$7.87M$9.1M$8.63M$8.02M
Research and development$25.29M$23.4M$21.9M$20.04M$31.69M$32.63M$29.79M$29.35M
Total operating expenses$33.62M$31.54M$30.12M$26.43M$39.56M$41.73M$38.42M$37.38M
Operating income-$33.03M-$30.49M-$29.14M-$23.86M-$37.05M-$38.65M-$36.25M-$36.71M
Interest expense-$775K-$699K-$689K-$702K-$699K-$689K-$679K-$784K
Income before taxes-$33.09M-$30.36M-$28.67M-$22.98M-$35.71M-$36.95M-$34.13M-$35.81M
Income taxes$0$0$0$0$0$0$0$0
Net income-$33.09M-$30.36M-$28.67M-$22.98M-$35.71M-$36.95M-$34.13M-$35.81M
Net income attributable to common shareholders-$33.09M-$30.36M-$28.67M-$22.98M-$35.71M-$36.95M-$34.13M-$35.81M
EBITDA-$32.35M-$29.79M-$28.45M-$23.14M-$36.29M-$37.96M-$35.57M-$36M
Basic earnings per share-$0.25-$0.23-$0.22-$0.18-$0.28-$0.28-$0.26-$0.30
Diluted earnings per share-$0.25-$0.23-$0.22-$0.18-$0.28-$0.28-$0.26-$0.30

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation

TScan Therapeutics reported positive results from Cohort C of its Phase 1 ALLOHA study of TSC-101, a TCR-engineered T cell therapy for hematologic malignancies. 11 of 14 patients achieved complete donor chimerism within three weeks of the first infusion, with all 5 patients assessed after a second infusion showing complete chimerism. The commercial-ready manufacturing process achieved a 90% success rate. The company remains on track to initiate its Phase 3 ALLOHA-2 study this month.

GlobeNewswire Inc.

TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

TScan Therapeutics reported Q1 2026 financial results with net loss of $28.7 million and revenue of $1.0 million. The company announced multiple clinical milestones including early data from Cohort C of its Phase 1 ALLOHA trial expected in Q2 2026, planned Phase 3 initiation of TSC-101 in Q2 2026, and Phase 1 studies of TSC-102-A01 and TSC-102-A03 in H2 2026. Cash position of $128.1 million is expected to fund operations into H2 2027.

GlobeNewswire Inc.

TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference

TScan Therapeutics, a clinical-stage biotech company developing TCR-engineered T cell therapies for cancer treatment, announced participation in the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026. The company reported completion of enrollment in Cohort C of its Phase 1 ALLOHA™ trial using a commercial-ready manufacturing process and received FDA clearance for investigational new drug applications for candidates TSC-102-A01 and TSC-102-A03.

GlobeNewswire Inc.

TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03

TScan Therapeutics completed enrollment in Cohort C of its Phase 1 ALLOHA™ trial using a commercial-ready manufacturing process and received FDA clearance for investigational new drug applications for TSC-102-A01 and TSC-102-A03 candidates targeting CD45 for patients with HLA types A*01:01 and A*03:01. The company plans to share safety and chimerism data in Q2 2026 and launch a pivotal trial for TSC-101, while initiating Phase 1 studies for both TSC-102 candidates in the second half of 2026.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.